GlassScriptPhysician profile
Timothy John Weibel
NPI 1548296437
$8,327.99
in general payments reported to CMS, 2019-2025
24 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,415 · 2020: $71.01 · 2021: $863 · 2022: $1,813 · 2023: $1,105 · 2024: $1,023 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,164.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,438.12 | 2019-2022 | |
| Musculoskeletal Transplant Foundation INC. | $1,284.62 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $820.28 | 2021-2025 | Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $596.57 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $433.94 | 2019-2020 | |
| Genzyme Corporation | $392.23 | 2023-2025 | |
| Abbvie INC. | $385.41 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $327.95 | 2023-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $313.86 | 2019-2021 | |
| Lilly USA, LLC | $248.68 | 2022-2023 | Olumiant |
| Celgene Corporation | $224.51 | 2019 | |
| Dilon Technologies, INC. | $204.52 | 2025 | Hemoblast Bellows |
| Davol INC. | $192.66 | 2021 | |
| Pfizer INC. | $188.83 | 2024 | |
| Journey Medical Corporation | $178.97 | 2021-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $139.83 | 2022 | |
| Dermavant Sciences, INC. | $136.16 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $125.17 | 2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $124.99 | 2021 | |
| Encore Dermatology INC. | $122.73 | 2019 | |
| Merz North America, INC. | $121.10 | 2022 | |
| Leo Pharma INC. | $120.04 | 2025 | Adbry |
| Revance Therapeutics, INC. | $107.05 | 2024 | Daxxify |
| Almirall LLC | $99.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Weibel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.